Heart Failure

Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.

The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.

A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

Drs James Januzzi, Javed Butler, Robert Mentz, and Muthiah Vaduganathan share practice pearls for treating patients with heart failure, focusing on the future of treatment.

Robert Mentz, MD, reviews the results of the STONG-HF trial for patients in the hospital for heart failure.

Anuradha Lala-Trindade, MD, shares developments in the pipeline for heart failure therapy, as well as clinical pearls for health care providers managing patients with heart failure.

Anuradha Lala-Trindade, MD, discusses the PARAGLIDE-HF trials, highlighting the use of sacubitril/valsartan for the management of heart failure in certain populations.

Experts in cardiology comment on the impact of recent trials on heart failure with preserved ejection fraction (HFpEF) in clinical practice.

Muthiah Vaduganathan, MD, MPH, provides an overview of the pooled data from the PARAGLIDE-HF and PARAGON-HF clinical trials in heart failure.

Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.

An expert cardiologist comments on unmet needs in the management of heart failure, highlighting the need to categorize patients with heart failure in order to better treat them.

Anuradha Lala-Trindade, MD, shares approaches to personalizing quadruple therapy for people with heart failure, focusing on family history, device-based therapies, and optimizing therapy early.

A new analysis suggests Black patients with NICM and an ICD had a high risk and burden of arrhythmia, with a lower survival rate, compared with White patients.

A new analysis from the American Heart Association found present-day heart failure risk was higher among Black adults who lived in areas historically impacted by redlining.

Experts in cardiology discuss the use of sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF), highlighting the PARAGLIDE-HF study.

Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).

Physical activity concentrated within a 1- to 2-day span was associated with a similarly lower risk of cardiovascular outcomes to more evenly distributed activity.

Anuradha Lala-Trindade, MD, provides an overview of SGLT2 inhibitors for the management of heart failure, as well as their clinical trial data.

An expert cardiologist reviews the foundational pillars of quadruple-based, guideline therapies for heart failure, as well as the contraindications for these drugs.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.